Unlocking Cancer’s Future: Aprea Therapeutics Targets Mutant p53 for Breakthrough Treatments
Discover how Aprea Therapeutics, a Boston‑based biopharma, is pioneering p53‑reactivating drugs to transform cancer care worldwide—financials, trials, and future prospects.
2 minutes to read